Bristol-Myers Squibb is weighing sale of UPSA

Bristol-Myers Squibb (BMS) is weighing up the potential sale of its France-based consumer healthcare operation, UPSA, and has launched a strategic review of the business to assess its future growth potential. Contrary to reports from Reuters, OTC bulletin understands that the New York-based biopharmaceutical giant has not yet made a decision on the future of the business.